Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
AMDX2011P in Amyotrophic Lateral Sclerosis: NCT05542576 Clinical Landscape Report 2026
16 October 2026
NCT05542576 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VRG-50635 in Amyotrophic Lateral Sclerosis: ISRCTN14792372 Clinical Landscape Report 2026
16 October 2026
ISRCTN14792372 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Disufenton Sodium in Glioblastoma Multiforme: NCT05561374 Clinical Landscape Report 2026
16 October 2026
NCT05561374 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zirconium (89Zr) girentuximabum senvedoxamum in Von Hippel-Lindau Disease: NCT05563272 Clinical Landscape Report 2026
16 October 2026
NCT05563272 clinical landscape for Von Hippel-Lindau Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NPVAC-2 in Glioblastoma: NCT05557240 Clinical Landscape Report 2026
16 October 2026
NCT05557240 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RMC-5552 in Recurrent Glioblastoma: NCT05557292 Clinical Landscape Report 2026
16 October 2026
NCT05557292 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Edaravone in Amyotrophic Lateral Sclerosis: NCT05568615 Clinical Landscape Report 2026
16 October 2026
NCT05568615 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Aminolevulinic Acid Hydrochloride in Glioblastoma: NCT05590689 Clinical Landscape Report 2026
16 October 2026
NCT05590689 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD44/CD133 targeted CAR-T(Tasly) in Recurrent Glioblastoma: NCT05577091 Clinical Landscape Report 2026
16 October 2026
NCT05577091 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT05589961 Clinical Landscape Report 2026
16 October 2026
NCT05589961 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT05600491 Clinical Landscape Report 2026
16 October 2026
NCT05600491 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
[11C]CPPC in Amyotrophic Lateral Sclerosis: NCT05602142 Clinical Landscape Report 2026
16 October 2026
NCT05602142 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.